Zhou Jian, Heng Yu, Yang Yue, Zhu Xiaoke, Zhou Liang, Gong Hongli, Xu Chengzhi, Tao Lei
Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai 200031, P.R. China.
Oncol Lett. 2022 Oct 19;24(6):434. doi: 10.3892/ol.2022.13554. eCollection 2022 Dec.
This study aimed to evaluate the clinical outcomes of patients with T3-4aN0M0 glottic laryngeal squamous cell carcinoma (LSCC) treated with laryngectomy, and to assess the postoperative radiotherapy (PORT) results in terms of the survival of T3-T4aN0M0 patients with negative margins. This was a retrospective review of 369 T3-4aN0M0 glottic LSCC cases. The 5-year cancer-specific survival (CSS) and overall survival (OS) rates were 67.5 and 66.7%, respectively. Patients who received total laryngectomy had worse survival [5-year CSS, 62.5%; disease-free survival (DFS), 56.2%] than those who underwent partial laryngectomy (5-year CSS, 79.3%; DFS, 65.4%). More advanced-stage cancer is a predictor of poor survival. There was no significant difference in CSS or DFS between patients with positive margins following rescue therapy and those with negative margins. Furthermore, no difference in the survival rates was observed between patients with negative margins who received PORT and those who did not (5-year DFS: 59.1 vs. 63.8%, P=0.057 and CSS: 62.5 vs. 69.5%, P=0.074). For T3-4aN0M0 glottic LSCC patients, surgical treatment remained a good option, as it can achieve satisfactory oncological outcomes. However, PORT did not increase survival in surgically managed pT3-4aN0M0 LSCC patients with negative margins.
本研究旨在评估接受喉切除术治疗的T3-4aN0M0声门型喉鳞状细胞癌(LSCC)患者的临床结局,并根据切缘阴性的T3-T4aN0M0患者的生存情况评估术后放疗(PORT)的效果。这是一项对369例T3-4aN0M0声门型LSCC病例的回顾性研究。5年癌症特异性生存率(CSS)和总生存率(OS)分别为67.5%和66.7%。接受全喉切除术的患者生存率较差[5年CSS为62.5%;无病生存率(DFS)为56.2%],低于接受部分喉切除术的患者(5年CSS为79.3%;DFS为65.4%)。癌症分期越晚是生存率低的一个预测因素。挽救治疗后切缘阳性的患者与切缘阴性的患者在CSS或DFS方面无显著差异。此外,接受PORT和未接受PORT的切缘阴性患者的生存率也无差异(5年DFS:59.1%对63.8%,P = 0.057;CSS:62.5%对69.5%,P = 0.074)。对于T3-4aN0M0声门型LSCC患者,手术治疗仍然是一个不错的选择,因为它可以实现令人满意的肿瘤学结局。然而,PORT并未提高手术治疗的切缘阴性的pT3-4aN0M0 LSCC患者的生存率。